SynthesisThe American journal of emergency medicine2021
Cardiac markers of multisystem inflammatory syndrome in children (MIS-C) in COVID-19 patients: A meta-analysis.
Synthesis in The American journal of emergency medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 4 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- Multisystem inflammatory syndrome in children: an Umbrella review.Journal of anesthesia · 2024Pooled it
- Evidence linking COVID-19 and the health/well-being of children and adolescents: an umbrella review.BMC medicine · 2024Pooled it
- Cardiac Injury in COVID-19: A Systematic Review of Relevant Meta-Analyses.Reviews in cardiovascular medicine · 2022Pooled it
- Multisystem Inflammatory Syndrome Associated With COVID-19 in Children (MIS-C): A Systematic Review of Studies From India.Indian pediatrics · 2022Pooled it
- Comparative Analysis of Routine Blood Laboratory Tests in Multisystem Inflammatory Syndrome in Children (MIS-C) and Kawasaki Disease Among White and Black Children.Pediatric cardiology · 2026Article
- Research Progress on Coronary Artery Injury and Myocardial Ischemia in Multisystem Inflammatory Syndrome in Children.Current issues in molecular biology · 2026Review
- Cardiogenic Shock Risk Score at Diagnosis of Multisystem Inflammatory Syndrome in Children: A Multicenter Study.Pediatric cardiology · 2026Observational
- Correlation of Clinical and Laboratory Features of Multisystem Inflammatory Syndrome in Children with Echocardiographic Findings.Medicina (Kaunas, Lithuania) · 2025Article
- Cardiac Manifestations and Emerging Biomarkers in Multisystem Inflammatory Syndrome in Children (MIS-C): A Systematic Review and Meta-Analysis.Life (Basel, Switzerland) · 2025Review
- Prognostic Value of Caspase-3 and Cardiac Troponin I in Assessing Cardiovascular Risk in Pediatric COVID-19 and Multisystem Inflammatory Syndrome.Journal of multidisciplinary healthcare · 2025Article
- Cardiac Biomarkers Aid in Differentiation of Kawasaki Disease from Multisystem Inflammatory Syndrome in Children Associated with COVID-19.Pediatric cardiology · 2025Article
- Prognostic Value of Baseline Serum Pro-Inflammatory Cytokines in Severe Multisystem Inflammatory Syndrome in Children.Journal of clinical medicine · 2024Article
- Severity predictors for multisystemic inflammatory syndrome in children after SARS-CoV-2 infection in Vietnam.Scientific reports · 2024Article
- [Cardiovascular manifestations in pediatric multisystem inflammatory syndrome associated with COVID-19 in a tertiary care pediatric center in Mexico City].Archivos de cardiologia de Mexico · 2024Observational
- NT-proBNP course during MIS-C post-COVID-19: an observational study.European journal of pediatrics · 2024Observational
- Clinical Predictors of Subacute Myocardial Dysfunction in Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID-19.Pediatric cardiology · 2024Article
- Multisystem inflammatory syndrome in children (MIS-C): A nationwide collaborative study in the Greek population.European journal of pediatrics · 2024Article
- Evaluation of clinical and laboratory findings in MIS-C patients associated with COVID-19: An experience from the Northwest of Iran.PloS one · 2024Article
- Description and outcomes of Afro-Caribbean children treated for multisystem inflammatory syndrome in the French West Indies.Heliyon · 2023Article
- N-Terminal Pro-B Type Natriuretic Peptide as a Predictive Biomarker of Bronchopulmonary Dysplasia or Death Due to Bronchopulmonary Dysplasia in Preterm Neonates: A Systematic Review and Meta-Analysis.Journal of personalized medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveA meta-analysis of laboratory cardiac markers for multisystem inflammatory syndrome in children (MIS-C) was performed in patients with coronavirus disease 2019 (COVID-19).
methodsEight databases were searched until April 10, 2021, for studies on cardiac markers, including B-type natriuretic peptide (BNP)/N-terminal pro-BNP (NT-proBNP), troponin, aspartate aminotransferase (AST), in MIS-C patients.
resultsOf the 2583 participants enrolled in 24 studies, 1613 patients were diagnosed with MIS-C. MIS-C patients exhibited higher BNP levels than patients with non-severe COVID-19 [SMD (95% CI): 1.13 (0.48, 1.77), p < 0.05]. No significant differences in BNP levels were observed between patients with MIS-C and severe COVID-19 [SMD (95% CI): 0.29 (-0.07, 0.65), p = 0.117]. Comparisons of MIS-C patients to all COVID-19 patients revealed no significant differences in levels of troponin [SMD (95% CI): 0.13 (-0.07, 0.32), p = 0.212] or AST [SMD (95% CI): 0.10 (-0.11, 0.31), p = 0.336]. Compared to patients with non-severe MIS-C, those with severe MIS-C exhibited higher levels of BNP [SMD (95% CI): 0.26 (0.04, 0.48), p < 0.05], but no differences in troponin [SMD (95% CI): 0.05 (-0.06, 0.16) p = 0.387] or AST [SMD (95% CI): 0.19 (-0.34, 0.71), p = 0.483] were observed. Moreover, there was no significant difference in BNP [SMD (95% CI): -0.21 (-1.07, 0.64), p = 0.624] or troponin [SMD (95% CI): -0.07 (-0.45, 0.31), p = 0.710] between MIS-C with and without coronary artery abnormality. Sensitivity analyses were performed to assess stability. No publication bias was detected based on Begg's test.
conclusionsThe key cardiac marker that showed differences between patients with MIS-C/non-severe COVID-19 and between patients with severe/non-severe MIS-C was BNP. Other markers, such as troponin and AST, did not exhibit notable differences in indicating cardiac injury between patients with MIS-C and COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.